primary endpoint

Type: Keyphrase
Name: primary endpoint
First reported 8 hours ago - Updated 6 hours ago - 1 reports

Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia Vera

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) today announced top-line results from RELIEF, a randomized, double-blind clinical trial designed to compare symptom improvement in 110 patients with polycythemia vera (PV) treated with ... [Published Investor's Business Daily - 8 hours ago]
First reported Jul 22 2014 - Updated 7 hours ago - 1 reports

Puma explodes AH

Shares of Puma Biotechnology (NYSE: PBYI ) skyrocket  186%  AH on massive volume after the company reported top-line results from its Phase 3 clinical trial evaluating PB272 ( neratinib ) as a treatment for HER2-positive breast cancer. The study, called ... [Published Seeking Alpha - Jul 22 2014]
Entities: Herceptin, adjuvant, Placebo
First reported 15 hours ago - Updated 7 hours ago - 2 reports

Inovio's HPV Immunotherapy Hits Primary Endpoint

Inovio Pharmaceuticals Inc. announced successful results from its randomized, double-blind, placebo-controlled Phase 2 trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) ... [Published Drug Discovery and Development - 7 hours ago]
First reported 12 hours ago - Updated 10 hours ago - 1 reports

Puma Pumps up Biotech ETFs

Shares of Puma Biotechnology (NYSE: PBYI) are up more than 277% Wednesday on volume that is already better than 10 times the daily average after the company said its experimental breast cancer treatment, neratinib, proved successful in a Phase III trial. ... [Published Street Sweeper - 12 hours ago]
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir

ViiV Healthcare today presented, at the 20th International AIDS Congress in Melbourne, Australia, the analysis of the 48-week results from the phase III MODERN study comparing maraviroc (MVC; marketed as Celsentri® /Selzentry®) dosed once daily with darunavir/ritonavir ... [Published European Pharmaceutical Review - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 1 reports

Genocea starts Phase 2 for herpes drug candidate

09:05 ET | About: Genocea Biosciences, Inc. (GNCA)Genocea Biosciences (NASDAQ:GNCA) commences a Phase 2 dose optimization trial for GEN-003, its immunotherapy candidate for herpes simplex-type 2 (HSV-2). The 300-patient 17-site study will evaluate six ... [Published Seeking Alpha - Jul 21 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Phase II trial kicks off for sublingually delivered Parkinson's therapy

A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.If all goes as planned on the regulatory front, the candidate, ... [Published Fierce Drug Delivery - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Anti-Amyloid Drug Has Mixed Results

COPENHAGEN (MedPage Today) -- The amyloid plaque-busting drug crenezumab for Alzheimer's disease slowed cognitive decline in patients with mild baseline impairment but missed its primary endpoint in a phase II trial. ... [Published MedPageToday.com - medical news plus CME for ph ... - Jul 21 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Aquinox Pharmaceuticals: A Compelling Risk/Reward Ahead Of Data

Summary Aquinox is developing a novel approach to treating inflammatory diseases and cancer. Oral drug candidate AQX-1125 has demonstrated positive efficacy and safety data in two proof of concept studies. Two near-term phase II trial readouts for ... [Published Seeking Alpha - Jul 21 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

FDA OK's Phase 2 study of Avanir MDD candidate

09:46 ET | About: Avanir Pharmaceuticals, Inc (AVNR)The FDA accepts Avanir Pharmaceuticals' (AVNR) IND for a Phase 2 trial evaluating the safety and efficacy of AVP-786, its product candidate for the adjunctive treatment of major depressive disorder ... [Published Seeking Alpha - Jul 21 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

PTH Drug Passes Test in Dialysis Patients

(MedPage Today) -- An investigational drug for secondary hyperparathyroidism in chronic kidney disease patients on dialysis met its primary endpoint, Amgen announced. ... [Published MedPageToday.com - medical news plus CME for ph ... - Jul 18 2014]
Entities: Dialysis, Patient, Drugs
First reported Jul 17 2014 - Updated Jul 18 2014 - 1 reports

Successful Phase 3 results for Amgen thyroid drug candidate

16:17 ET | About: Amgen Inc. (AMGN)A Phase 3 clinical trial evaluating the safety and efficacy of Amgen's (AMGN -2%) AMG 416 (formerly velcalcetide) as a treatment of secondary hyperthyroidism achieves its primary endpoint and all secondary endpoints. ... [Published Seeking Alpha - Jul 17 2014]

Quotes

...anagement," said Steven J Romano , M D , senior vice president and Medicines Development Group Head, Global Innovative Pharmaceuticals , Pfizer Inc. " Pfizer remains committed to the researchresearch and development of new and innovative products for the hemophilia community."
"We thank the women who participated and the clinical investigators who provided patient care and made this trial possible" Kim said
...According to news reporting originating from Frankfurt, Germany , by NewsRx correspondents, research stated, "This study sought to assess the efficacy of catheter-based renal sympathetic denervation in patients with accessory renal arteries and to compare the bloodblood pressure (BP)-lowering effect with that observed in patients with bilateral single renal arteries after renal denervation. Catheter-based renal sympathetic denervation causes significant BP reductions in patients with resistant hypertension."
...atment-naive patients when compared to a standard three-drug regimen of tenofovir emtricitabine plus darunavir/ritonavir, the researchers concluded. "There was no treatment-emergent resistance in either arm. There was comparable safety and no unexpected safety findings."

More Content

All (1227) | News (1040) | Reports (0) | Blogs (160) | Audio/Video (0) | Fact Sheets (1) | Press Releases (17)
sort by: Date | Relevance
Pfizer : Announces Positive Top-Line Results Fr... [Published 4 Traders - 2 hours ago]
Healthcare Review: Biogen Idec, Inovio Pharmace... [Published BioMedReports - 4 hours ago]
Is Inovio Undervalued After Positive HPV Therap... [Published BioPortfolio - 5 hours ago]
Incyte's Jakafi fails label expansion trial [Published Seeking Alpha - 6 hours ago]
Incyte Corp announces top-line results from REL... [Published Reuters - 6 hours ago]
Inovio's HPV Immunotherapy Hits Primary Endpoint [Published Drug Discovery and Development - 7 hours ago]
Breast Cancer–Related Benefits of Weight Loss [Published The ASCO Post - 7 hours ago]
Adding Novel Agent to Standard Therapy Improves... [Published The ASCO Post - 7 hours ago]
Incyte Announces Top-Line Results from RELIEF T... [Published Investor's Business Daily - 8 hours ago]
Is Inovio Undervalued After Positive HPV Therap... [Published Seeking Alpha - 8 hours ago]
Incyte Announces Top-Line Results from RELIEF T... [Published EON Science - 8 hours ago]
Impressive Delay in Thyroid Cancer Progression ... [Published The ASCO Post - 8 hours ago]
Multiple Myeloma Studies Explore Roles of Panob... [Published The ASCO Post - 8 hours ago]
Phase III Trial Shows Improved Survival With TA... [Published The ASCO Post - 8 hours ago]
Incyte Announces Top-Line Results from RELIEF T... [Published Business Wire Science: Science News - 8 hours ago]
Incyte Announces Top-Line Results from RELIEF T... [Published Business Wire Health News - 8 hours ago]
Puma Biotechnology Stock Is Flying; Time to Buy? [Published Motley Fool Discussion Boards - 9 hours ago]
Findings from CardioVascular Center Update Unde... [Published 4 Traders - 9 hours ago]
Positive Phase III Results Reported for Brivara... [Published PT Community - 10 hours ago]
Breast Cancer Drug Neratanib Meets Trial Goal [Published PT Community - 10 hours ago]
AIDS 2014: Maraviroc Fails To Match Truvada for... [Published HIV and Hepatitis.com - 10 hours ago]
ODAC Votes No on Accelerated Approval of Olapar... [Published Oncology Times - 10 hours ago]
Puma Biotech Surges on Positive Results on Nera... [Published Yahoo! Finance - 11 hours ago]
Inovio vs. Feuerstein, Round II: Biotech claims... [Published FierceBiotech - 11 hours ago]
Celator: A Unique Drug Ratio Technology Company... [Published Seeking Alpha - 11 hours ago]
Puma Pumps up Biotech ETFs [Published Yahoo! Finance - 12 hours ago]
Major Advance In Pipeline: Positive Topline Pha... [Published BioSpace - 12 hours ago]
Puma Biotechnology Shares Soar On Breast Cancer... [Published BioSpace - 12 hours ago]
Puma Pumps up Biotech ETFs [Published Street Sweeper - 12 hours ago]
Puma Biotechnology Seen as Takeover Target Afte... [Published TheStreet.com - 12 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Incyte Announces Top-Line Results from RELIEF T... [Published EON Science - 8 hours ago]
WILMINGTON, Del.--(EON: Enhanced Online News)--Incyte Corporation (Nasdaq: INCY) today announced top-line results from RELIEF, a randomized, double-blind clinical trial designed to compare symptom improvement in 110 patients with polycythemia vera (PV) ...
Incyte Announces Top-Line Results from RELIEF T... [Published Business Wire Science: Science News - 8 hours ago]
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced top-line results from RELIEF, a randomized, double-blind clinical trial designed to compare symptom improvement in 110 patients with polycythemia vera (PV) treated with ...
Incyte Announces Top-Line Results from RELIEF T... [Published Business Wire Health News - 8 hours ago]
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced top-line results from RELIEF, a randomized, double-blind clinical trial designed to compare symptom improvement in 110 patients with polycythemia vera (PV) treated with ...
A Biotech Stock Is Up Nearly 300% After Announc... [Published Clusterstock - 14 hours ago]
Shares of Puma Biotechnology are up 296% right now. On Tuesday evening, the company announced encouraging results from its recent breast cancerdrug  trial. "[A] clinical trial of its experimental drug blocked the return of breast cancer in women ...
Anti-Amyloid Drug Has Mixed Results [Published MedPageToday.com - medical news plus CME for ph ... - Jul 21 2014]
COPENHAGEN (MedPage Today) -- The amyloid plaque-busting drug crenezumab for Alzheimer's disease slowed cognitive decline in patients with mild baseline impairment but missed its primary endpoint in a phase II trial. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Sanofi and Regeneron Announce Positive Results ... [Published GlobeNewswire: Acquisitions News - Jul 09 2014]
GSK and Genmab announce top-line results from a... [Published GlobeNewswire: Advertising News - Jun 27 2014]
Lundbeck provides update on the development pro... [Published GlobeNewswire: Acquisitions News - Jun 27 2014]
DGAP-News: PAION REPORTS POSITIVE PHASE II RESU... [Published GlobeNewswire: Advertising News - May 28 2014]
Continuing progress in accelerating late stage ... [Published AstraZeneca - May 15 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.